by Tacrolimus, also known as FK506, is a calcineurin inhibitor immunosuppressant drug used to prevent rejection in organ transplantation. It works by inhibiting T-cell activation and interleukin-2 transcription. Tacrolimus is effective in preventing rejection in liver, kidney, and heart allografts.
The global Tacrolimus market is estimated to be valued at US$ 7822.21 billion in 2024 and is expected to exhibit a CAGR of 7.1% over the forecast period from 2024 to 2030.
Key Takeaways
Key players operating in the Tacrolimus market are Domtar Corporation, Medline Industries Inc., Cardinal Health, Attends Healthcare Products Inc., Kimberly-Clark Corporation, Dynarex Corporation, Tanga.com, Sarasota Medical, SCA, First Quality Enterprises Inc., Prevail, Cypress Medical Products LLC, Shield Healthcare LLC, 3M, McKesson Corporation, Ontex.
The growing number of organ transplantation procedures being performed globally is a major factor driving the demand for Tacrolimus. Tacrolimus improves organ transplant survival rates and quality of life for recipients. According to the NIH, the number of organ transplants performed annually has increased from approximately 20,000 transplants in 1988 to over 30,000 transplants currently in the United States alone.
The market is also witnessing increased growth opportunities in emerging economies in Asia Pacific, Latin America, and Middle East & Africa. This is attributed to increasing healthcare expenditures, rising awareness about transplantation, and growing incidence of end-stage organ failures in these regions. Key players are focusing on expanding their presence in high growth markets to leverage new revenue sources.
Market key trends
One of the key trends prevailing in The Tacrolimus Market is the development of extended-release formulations with improved pharmacokinetic profiles. Extended-release formulations allow for once-daily dosing as compared to the conventional twice-daily immediate-release capsules. This enhances patient compliance and convenience. Major players have received FDA approval for proprietary extended-release formulations such as Envarsus XR (Veloxis), Astagraf XL (Chiesi) and Envarius (Veloxis).
Porter’s Analysis
Threat of new entrants: Require large-scale manufacturing capabilities and regulatory approvals which make entry difficult for new players.
Bargaining power of buyers: Large buyers collaborate to negotiate better prices and contracts from established suppliers in this market.
Bargaining power of suppliers: A few multinational companies dominate the supply market.
Threat of new substitutes: No viable substitutes currently exist for tacrolimus which is an effective immunosuppressant drug.
Competitive rivalry: Intense competition exists between major existing players to gain higher market share.
Geographical Regions
North America currently accounts for the largest share of the global tacrolimus market in terms of value due to high adoption and favorable reimbursement scenario.
The Asia Pacific region is expected to be the fastest growing regional market during the forecast period owing to rising healthcare expenditures, increasing generic drug innovation and growing patient pool in major countries like China and India.
